Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP-R212 in Hypertension and Hypercholesterolemia
NCT02955368Phase 3Withdrawn
- Sponsor
- Alvogen
- Start
- Feb 2017
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of amlodipine and rosuvastatin in hypertension (HTN) and hypercholesterolemia (3 arms), sponsored by Alvogen. Primary endpoints: Percent change of LDL-Cholesterol at 8 weeks and Change of mean seated Systolic Blood Pressure at 8 weeks. Planned start Feb 2017; status: withdrawn.
02
Drugs
amlodipinerosuvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02955368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955368.